JP2012507271A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507271A5
JP2012507271A5 JP2011533752A JP2011533752A JP2012507271A5 JP 2012507271 A5 JP2012507271 A5 JP 2012507271A5 JP 2011533752 A JP2011533752 A JP 2011533752A JP 2011533752 A JP2011533752 A JP 2011533752A JP 2012507271 A5 JP2012507271 A5 JP 2012507271A5
Authority
JP
Japan
Prior art keywords
amino acid
acid residue
group
residue selected
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507271A (ja
JP5954990B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064483 external-priority patent/WO2010060748A1/en
Publication of JP2012507271A publication Critical patent/JP2012507271A/ja
Publication of JP2012507271A5 publication Critical patent/JP2012507271A5/ja
Application granted granted Critical
Publication of JP5954990B2 publication Critical patent/JP5954990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533752A 2008-11-03 2009-11-03 Vegf−aレセプター相互作用を阻害する結合タンパク質 Active JP5954990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168166.0 2008-11-03
EP08168166 2008-11-03
PCT/EP2009/064483 WO2010060748A1 (en) 2008-11-03 2009-11-03 Binding proteins inhibiting the vegf-a receptor interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015053249A Division JP6329503B2 (ja) 2008-11-03 2015-03-17 Vegf−aレセプター相互作用を阻害する結合タンパク質

Publications (3)

Publication Number Publication Date
JP2012507271A JP2012507271A (ja) 2012-03-29
JP2012507271A5 true JP2012507271A5 (cg-RX-API-DMAC7.html) 2012-11-29
JP5954990B2 JP5954990B2 (ja) 2016-07-20

Family

ID=40149742

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011533752A Active JP5954990B2 (ja) 2008-11-03 2009-11-03 Vegf−aレセプター相互作用を阻害する結合タンパク質
JP2015053249A Active JP6329503B2 (ja) 2008-11-03 2015-03-17 Vegf−aレセプター相互作用を阻害する結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015053249A Active JP6329503B2 (ja) 2008-11-03 2015-03-17 Vegf−aレセプター相互作用を阻害する結合タンパク質

Country Status (15)

Country Link
US (2) US8901076B2 (cg-RX-API-DMAC7.html)
EP (2) EP3785735A1 (cg-RX-API-DMAC7.html)
JP (2) JP5954990B2 (cg-RX-API-DMAC7.html)
KR (1) KR101698362B1 (cg-RX-API-DMAC7.html)
CN (2) CN102272148A (cg-RX-API-DMAC7.html)
AU (1) AU2009319204B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921469B1 (cg-RX-API-DMAC7.html)
CA (1) CA2742241C (cg-RX-API-DMAC7.html)
DK (1) DK2358746T3 (cg-RX-API-DMAC7.html)
ES (1) ES2836948T3 (cg-RX-API-DMAC7.html)
IL (1) IL212589A (cg-RX-API-DMAC7.html)
MX (2) MX2011004649A (cg-RX-API-DMAC7.html)
NZ (1) NZ592591A (cg-RX-API-DMAC7.html)
RU (2) RU2650765C1 (cg-RX-API-DMAC7.html)
WO (1) WO2010060748A1 (cg-RX-API-DMAC7.html)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
AU2014243418B2 (en) * 2010-04-30 2016-09-22 Molecular Partners Ag Modified binding proteins inhibiting the VEGF-A receptor interaction
AR081361A1 (es) * 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
DK2643349T3 (da) * 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
MY178654A (en) 2011-11-16 2020-10-20 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
EP4086283A1 (en) 2011-11-16 2022-11-09 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
KR102249078B1 (ko) 2011-11-16 2021-05-10 아드레노메드 아게 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
HRP20190122T1 (hr) 2011-11-16 2019-03-08 Adrenomed Ag Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
CN103308689B (zh) 2012-03-08 2017-04-12 思芬构技术有限公司 用于预测雌性对象中患上癌症的风险或诊断癌症的方法
CN103308673B (zh) 2012-03-08 2017-05-31 思芬构技术有限公司 用于预测雌性对象中发生心血管事件的风险的方法
CN103308670B (zh) 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
HUE046134T2 (hu) * 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
AU2013269594C1 (en) 2012-06-01 2020-12-17 Novartis Ag Syringe
EP2867360B1 (en) * 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
JP2015528454A (ja) * 2012-08-28 2015-09-28 ノバルティス アーゲー 眼血管増殖性疾患の処置におけるvegfアンタゴニストの使用
RU2679913C2 (ru) 2012-10-02 2019-02-14 Сфинготек Гмбх Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CA2897327A1 (en) 2013-01-08 2014-07-17 Sphingotec Gmbh Fasting levels of growth hormone as a predictive marker of cardiovascular risk
WO2014131694A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2014151725A1 (en) * 2013-03-14 2014-09-25 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
SG10201800309SA (en) 2013-03-20 2018-02-27 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
EP3010525A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
US20160129080A1 (en) 2013-06-20 2016-05-12 Aaron Osborne Treatment of polypoidal chroidal vasculopathy
US20160130321A1 (en) 2013-06-20 2016-05-12 Gabriela Burian Use of a vegf antagonist in treating macular edema
RU2676303C2 (ru) 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
EP3019526A1 (en) 2013-07-11 2016-05-18 Novartis AG Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
SG11201510315TA (en) 2013-07-12 2016-01-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
PL3065761T3 (pl) * 2013-11-05 2020-05-18 Allergan, Inc. Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
EP3002589A1 (en) 2014-10-01 2016-04-06 sphingotec GmbH A method for stratifying a female subject for hormone replacement therapy
WO2016156596A1 (en) * 2015-04-02 2016-10-06 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
WO2016170023A1 (en) 2015-04-24 2016-10-27 Sphingotec Gmbh A method for predicting the risk of incidence of chronic kidney disease
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
EP3377151A1 (en) 2015-11-18 2018-09-26 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
MX382662B (es) 2015-11-18 2025-03-11 Sio2 Medical Products Inc Envase farmacéutico para formulaciones oftálmicas.
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
WO2017148904A1 (en) 2016-02-29 2017-09-08 Franz Grus Predictive markers useful in the treatment of wet age-related macular degeneration
DE112017002105T5 (de) 2016-04-21 2019-04-25 Sphingotec Therapeutics Gmbh Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren
MA45493A (fr) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
CN109716136B (zh) 2016-07-08 2023-09-22 斯弗因高泰克有限公司 肾上腺髓质素用于评估急性心力衰竭患者的充血
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
MX377424B (es) 2016-09-22 2025-03-10 Molecular Partners Ag Proteinas de union recombinantes y sus usos
EP3309550A1 (en) 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
EP3339324A1 (en) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
RU2021135712A (ru) 2016-12-16 2021-12-30 Адреномед Аг АНТИТЕЛО ПРОТИВ АДРЕНОМЕДУЛЛИНА (ADM), ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM не-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ ПРИ ВМЕШАТЕЛЬСТВЕ И ТЕРАПИИ ГИПЕРЕМИИ У ПАЦИЕНТА
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
US20200182885A1 (en) 2017-05-30 2020-06-11 Sphingotec Gmbh A method for diagnosing or monitoring kidney function or diagnosing kidney dysfuntion
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
SG11202001420VA (en) 2017-08-18 2020-03-30 Cambridge Entpr Ltd Modular binding proteins
RS66415B1 (sr) 2017-09-25 2025-02-28 Adrenomed Ag Anti-adrenomedulin (adm) – vezujući entitet za upotrebu u terapiji ili prevenciji simptoma bolesti
JP2021500548A (ja) 2017-10-18 2021-01-07 アドレノメト アクチェンゲゼルシャフト 抗アドレノメデュリン(adm)結合剤での処置下での治療モニタリング
RU2020115377A (ru) 2017-10-24 2021-11-25 Сфинготек Гмбх Селенопротеин p для прогнозирования первого сердечно-сосудистого явления
JP7424972B2 (ja) 2017-10-25 2024-01-30 4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 特定のdpp3エピトープに指向され、そしてそれに結合するdpp3バインダー、ならびに酸化ストレスに関連する疾患/急性病態の予防または治療におけるその使用
US20210302440A1 (en) 2018-02-08 2021-09-30 Sphingotec Gmbh Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
SG11202105176QA (en) 2018-12-20 2021-06-29 Sphingotec Gmbh Selenoprotein p in heart failure
CN113557031A (zh) 2018-12-21 2021-10-26 4Teen4制药有限公司 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测
EP3980443A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Multispecific proteins
BR112022001417A2 (pt) 2019-08-15 2022-05-24 Sphingotec Gmbh Método para diagnóstico ou monitoramento de função renal ou diagnóstico de disfunção renal em pacientes pediátricos
MX2022002432A (es) 2019-08-30 2022-06-02 4TEEN4 Pharmaceuticals GmbH Orientacion terapeutica y/o monitoreo terapeutico para el tratamiento de choques.
WO2021116462A1 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
EP3871689A1 (en) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
JP2023515985A (ja) 2020-02-27 2023-04-17 アドレノメト アクチェンゲゼルシャフト ショック状態の患者の治療において使用するための抗アドレノメデュリン(adm)結合剤
JP2023515042A (ja) 2020-02-27 2023-04-12 アドレノメト アクチェンゲゼルシャフト ショックの治療若しくは予防において使用するための抗アドレノメデュリン(ADM)抗体若しくは抗ADM抗体フラグメント又は抗ADM非Ig足場
AU2021228207A1 (en) 2020-02-27 2022-10-20 4TEEN4 Pharmaceuticals GmbH DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
BR112022017277A2 (pt) 2020-03-16 2022-10-18 4TEEN4 Pharmaceuticals GmbH Dpp3 em pacientes infectados com coronavírus
KR20220154743A (ko) 2020-03-16 2022-11-22 아드레노메드 아게 코로나 바이러스에 감염된 환자에서 프로-아드레노메둘린 또는 그의 단편, 및 아드레노메둘린에 대한 결합제에 의한 치료
TW202208404A (zh) 2020-05-06 2022-03-01 瑞士商分子組合公司 新穎錨蛋白重複結合蛋白質及其用途
CN115768786A (zh) 2020-05-14 2023-03-07 分子合作伙伴股份公司 多特异性蛋白质
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
US20240150475A1 (en) 2021-03-09 2024-05-09 Molecular Partners Ag Novel darpin based cd123 engagers
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
JP2024509904A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なDARPinに基づく多重特異性T細胞エンゲージャ
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
JP2024526081A (ja) 2021-06-18 2024-07-17 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 敗血症及び敗血症性ショックを予測する方法
EP4363859A1 (en) 2021-06-29 2024-05-08 berYsol GmbH Composite biomarker for the identification of selenium deficiency in a bodily fluid
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
AU2022413461A1 (en) 2021-12-14 2024-06-06 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
US20250304671A1 (en) 2022-03-15 2025-10-02 Adrenomed Ag Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
EP4562035A1 (en) 2022-07-29 2025-06-04 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
CN119731200A (zh) 2022-08-01 2025-03-28 分子合作伙伴股份公司 经电荷修饰设计的重复结构域及其用途
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024059686A2 (en) * 2022-09-15 2024-03-21 The Regents Of The University Of California Darpin backbones and rigidified electron microscopy imaging scaffolds
CN120359042A (zh) 2022-12-15 2025-07-22 4Teen4制药有限公司 改善危重病患者肺功能的dpp3抑制剂
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
CN120731367A (zh) 2023-03-17 2025-09-30 Pam治疗诊断有限公司 肽基甘氨酸α-酰胺化单加氧酶(PAM)的测定方法及其诊断用途
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
WO2025068313A1 (en) 2023-09-25 2025-04-03 Sphingotec Gmbh A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025229075A1 (en) 2024-05-03 2025-11-06 Sphingotec Gmbh A method for the specific determination of proenkephalin fragment 119-159
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
SI1325932T1 (cg-RX-API-DMAC7.html) 1997-04-07 2005-08-31 Genentech Inc
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
DE69935248T2 (de) 1998-12-02 2007-11-08 Adnexus Therapeutics, Inc., Waltham Dna-protein fusionen sowie anwendungen derselben
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
IL146890A0 (en) 1999-06-08 2002-08-14 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
ES2335861T3 (es) * 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
RU2299208C2 (ru) * 2001-05-08 2007-05-20 Шеринг Акциенгезельшафт Антраниламидпиридинамиды избирательного действия в качестве ингибиторов vegfr-2 и vegfr-3
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
AU2005303912B2 (en) * 2004-11-12 2011-02-17 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
DK2586459T3 (en) * 2005-03-25 2017-09-11 Regeneron Pharma VEGF antagonist formulations
WO2007006665A1 (en) 2005-07-08 2007-01-18 University Of Zürich Phage display using cotranslational translocation of fusion polypeptides
JP5537946B2 (ja) * 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Igf−irを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
TW200838875A (en) * 2007-02-01 2008-10-01 Genentech Inc Combination therapy with angiogenesis inhibitors
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade

Similar Documents

Publication Publication Date Title
JP2012507271A5 (cg-RX-API-DMAC7.html)
RU2011122201A (ru) Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
JP2015522576A5 (cg-RX-API-DMAC7.html)
JP2008508859A5 (cg-RX-API-DMAC7.html)
JP2013534812A5 (cg-RX-API-DMAC7.html)
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2014501510A5 (cg-RX-API-DMAC7.html)
JP2012525844A5 (cg-RX-API-DMAC7.html)
RU2014150224A (ru) Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
JP2006506942A5 (cg-RX-API-DMAC7.html)
JP2011502479A5 (cg-RX-API-DMAC7.html)
JP2009511579A5 (cg-RX-API-DMAC7.html)
JP2012531889A5 (cg-RX-API-DMAC7.html)
JP2019506841A5 (cg-RX-API-DMAC7.html)
JP2010519252A5 (cg-RX-API-DMAC7.html)
JP2010519931A5 (cg-RX-API-DMAC7.html)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
JP2018522563A5 (cg-RX-API-DMAC7.html)
JP2012082206A5 (cg-RX-API-DMAC7.html)
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
JP2010273685A5 (cg-RX-API-DMAC7.html)
JP2020503262A5 (ja) アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
JP2014520120A5 (cg-RX-API-DMAC7.html)
JP2008525033A5 (cg-RX-API-DMAC7.html)
JP2012115277A5 (cg-RX-API-DMAC7.html)